EPO-induced breast cancer cell migration was blocked by the PARP inhibitor Veliparib (ABT-888), suggesting an essential role for polyADP-ribosylation in this process and suggesting a new cancer-associated anemia treatment modality with combined administration of EPO and PARP inhibitors (92). This evidence concerns the gene EPO and anemia (phenotype).